Shopping Cart 0
Cart Subtotal
USD 0

PerkinElmer Inc (PKI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

PerkinElmer Inc (PerkinElmer) is a provider of detection and imaging technologies, consumables, informatics solutions, accessories and services to diagnostics, research, food, laboratory services, environmental, and industrial markets. The company's major products include cytogenetics reagents, ELISA Kits, tissue biomarker reagents, atomic spectroscopy instruments, chromatography instruments, molecular spectroscopy, newborn screening instruments and thermal analysis instruments, among others. It offers reagents, instruments, assay platforms and software to hospitals, clinicians, medical labs and medical research professionals. PerkinElmer also offers cord blood and tissue banking, laboratory and research services, among others. Its products are used in various applications, including atomic spectroscopy, cell imaging and analysis, chromatography, DNA/RNA isolation, analysis and detection, in vivo imaging, molecular spectroscopy, protein analysis and detection, and tissue imaging, among others. The company operates in Asia-Pacific, Europe and North America, among others. PerkinElmer is headquartered in Waltham, Massachusetts, US.

PerkinElmer Inc (PKI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PerkinElmer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

PerkinElmer Inc, Medical Devices Deals, 2012 to YTD 2018 10

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Enzyvant Enters into Collaboration Agreement PerkinElmer 13

Nightingale Health Enters into Agreement with PerkinElmer 14

PerkinElmer Forms Joint Venture with Genome Institute of Singapore 15

Albany Molecular Research Enters into Agreement with PerkinElmer 16

Reproductive Health Science Enters into Distribution Agreement with Delfran Pharma 17

Transgenomic Enters Into Co-Marketing Agreement With PerkinElmer For Oncology Diagnostic Test Portfolio 18

ViaCord Enters Into Agreement With Center for International Blood and Marrow Transplant Research For Stem Cell Therapy Research 19

PerkinElmer Enters Into Agreement With National Center for Drug Screening 20

Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 21

Integromics Enters Into Co-Development Agreement With Galician Foundation Of Genomic Medicine 22

Licensing Agreements 23

Bioo Scientific Enters into Licensing Agreement with Icahn School of Medicine 23

Trinean Enters Into Licensing Agreement With Perkinelmer For Microfluidics Technology 24

Debt Offering 25

PerkinElmer Raises USD370.1 Million in Public Offering of 0.6% Notes Due 2021 25

PerkinElmer Raises EUR553 Million in Public Offering of 1.875% Notes Due 2026 26

Acquisition 27

PerkinElmer to Acquire RHS for up to USD19.7 Million 27

PerkinElmer Acquires Bioo Scientific for USD63.5 Million 28

PerkinElmer Acquires Ceiba Solutions 29

AO Energy Completes Acquisition of Reproductive Health Science 30

PerkinElmer Acquires Shanghai Haoyuan Biotech From Medigen Biotech 31

PerkinElmer Inc-Key Competitors 32

PerkinElmer Inc-Key Employees 33

PerkinElmer Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Joint Venture 39

Recent Developments 40

Strategy And Business Planning 40

Sep 21, 2017: State Key Laboratory of Biochemical Engineering and PerkinElmer Open Joint Translational Medical Engineering Demonstration Laboratory in Beijing 40

Financial Announcements 41

Aug 01, 2018: PerkinElmer Announces Financial Results for the Second Quarter of 2018 41

Apr 30, 2018: PerkinElmer Reports Financial Results for the First Quarter of 2018 42

Jan 25, 2018: PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2017 43

Nov 02, 2017: PerkinElmer Announces Financial Results for the Third Quarter of 2017 45

Aug 03, 2017: PerkinElmer Announces Financial Results for the Second Quarter of 2017 46

May 04, 2017: PerkinElmer Announces Financial Results for the First Quarter of 2017 47

Feb 02, 2017: PerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2016 48

Corporate Communications 50

Apr 10, 2018: PerkinElmer Names James Mock as Chief Financial Officer 50

Oct 30, 2017: PerkinElmer Elects Pascale Witz to its Board of Directors 51

Sep 15, 2017: PerkinElmer Announces Future Retirement of Andy Wilson, Chief Financial Officer 52

Product News 53

Oct 31, 2017: Phase II Clinical Trial Data Establishes Effectiveness of using a Child's Own Cord Blood to Treat Cerebral Palsy 53

Mar 23, 2017: PerkinElmer to Display Portfolio of Cancer Research Technologies and Workflow Solutions at 2017 AACR Annual Meeting 54

Jan 23, 2017: PerkinElmer's NexION 2000 ICP-MS Provides Industry-Leading Versatility for Trace Elemental Analyses 56

Other Significant Developments 57

Apr 05, 2018: Parent Project Muscular Dystrophy Selects PerkinElmer to Support Decode Duchenne Program 57

Sep 07, 2017: PerkinElmer Extends Clinical Whole Genome Sequencing Services 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

PerkinElmer Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

PerkinElmer Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PerkinElmer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PerkinElmer Inc, Deals By Therapy Area, 2012 to YTD 2018 9

PerkinElmer Inc, Medical Devices Deals, 2012 to YTD 2018 10

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Enzyvant Enters into Collaboration Agreement PerkinElmer 13

Nightingale Health Enters into Agreement with PerkinElmer 14

PerkinElmer Forms Joint Venture with Genome Institute of Singapore 15

Albany Molecular Research Enters into Agreement with PerkinElmer 16

Reproductive Health Science Enters into Distribution Agreement with Delfran Pharma 17

Transgenomic Enters Into Co-Marketing Agreement With PerkinElmer For Oncology Diagnostic Test Portfolio 18

ViaCord Enters Into Agreement With Center for International Blood and Marrow Transplant Research For Stem Cell Therapy Research 19

PerkinElmer Enters Into Agreement With National Center for Drug Screening 20

Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 21

Integromics Enters Into Co-Development Agreement With Galician Foundation Of Genomic Medicine 22

Bioo Scientific Enters into Licensing Agreement with Icahn School of Medicine 23

Trinean Enters Into Licensing Agreement With Perkinelmer For Microfluidics Technology 24

PerkinElmer Raises USD370.1 Million in Public Offering of 0.6% Notes Due 2021 25

PerkinElmer Raises EUR553 Million in Public Offering of 1.875% Notes Due 2026 26

PerkinElmer to Acquire RHS for up to USD19.7 Million 27

PerkinElmer Acquires Bioo Scientific for USD63.5 Million 28

PerkinElmer Acquires Ceiba Solutions 29

AO Energy Completes Acquisition of Reproductive Health Science 30

PerkinElmer Acquires Shanghai Haoyuan Biotech From Medigen Biotech 31

PerkinElmer Inc, Key Competitors 32

PerkinElmer Inc, Key Employees 33

PerkinElmer Inc, Other Locations 34

PerkinElmer Inc, Subsidiaries 35

PerkinElmer Inc, Joint Venture 39

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

PerkinElmer Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

PerkinElmer Inc (PerkinElmer) is a provider of detection and imaging technologies, consumables, informatics solutions, accessories and services to diagnostics, research, food, laboratory services, environmental, and industrial markets. The company's major products include cytogenetics reagents, ELISA Kits, tissue biomarker reagents, atomic spectroscopy instruments, chromatography instruments, molecular spectroscopy, newborn screening instruments and thermal analysis instruments, among others. It offers reagents, instruments, assay platforms and software to hospitals, clinicians, medical labs and medical research professionals. PerkinElmer also offers cord blood and tissue banking, laboratory and research services, among others. Its products are used in various applications, including atomic spectroscopy, cell imaging and analysis, chromatography, DNA/RNA isolation, analysis and detection, in vivo imaging, molecular spectroscopy, protein analysis and detection, and tissue imaging, among others. The company operates in Asia-Pacific, Europe and North America, among others. PerkinElmer is headquartered in Waltham, Massachusetts, US.

PerkinElmer Inc (PKI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PerkinElmer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

PerkinElmer Inc, Medical Devices Deals, 2012 to YTD 2018 10

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Enzyvant Enters into Collaboration Agreement PerkinElmer 13

Nightingale Health Enters into Agreement with PerkinElmer 14

PerkinElmer Forms Joint Venture with Genome Institute of Singapore 15

Albany Molecular Research Enters into Agreement with PerkinElmer 16

Reproductive Health Science Enters into Distribution Agreement with Delfran Pharma 17

Transgenomic Enters Into Co-Marketing Agreement With PerkinElmer For Oncology Diagnostic Test Portfolio 18

ViaCord Enters Into Agreement With Center for International Blood and Marrow Transplant Research For Stem Cell Therapy Research 19

PerkinElmer Enters Into Agreement With National Center for Drug Screening 20

Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 21

Integromics Enters Into Co-Development Agreement With Galician Foundation Of Genomic Medicine 22

Licensing Agreements 23

Bioo Scientific Enters into Licensing Agreement with Icahn School of Medicine 23

Trinean Enters Into Licensing Agreement With Perkinelmer For Microfluidics Technology 24

Debt Offering 25

PerkinElmer Raises USD370.1 Million in Public Offering of 0.6% Notes Due 2021 25

PerkinElmer Raises EUR553 Million in Public Offering of 1.875% Notes Due 2026 26

Acquisition 27

PerkinElmer to Acquire RHS for up to USD19.7 Million 27

PerkinElmer Acquires Bioo Scientific for USD63.5 Million 28

PerkinElmer Acquires Ceiba Solutions 29

AO Energy Completes Acquisition of Reproductive Health Science 30

PerkinElmer Acquires Shanghai Haoyuan Biotech From Medigen Biotech 31

PerkinElmer Inc-Key Competitors 32

PerkinElmer Inc-Key Employees 33

PerkinElmer Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Joint Venture 39

Recent Developments 40

Strategy And Business Planning 40

Sep 21, 2017: State Key Laboratory of Biochemical Engineering and PerkinElmer Open Joint Translational Medical Engineering Demonstration Laboratory in Beijing 40

Financial Announcements 41

Aug 01, 2018: PerkinElmer Announces Financial Results for the Second Quarter of 2018 41

Apr 30, 2018: PerkinElmer Reports Financial Results for the First Quarter of 2018 42

Jan 25, 2018: PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2017 43

Nov 02, 2017: PerkinElmer Announces Financial Results for the Third Quarter of 2017 45

Aug 03, 2017: PerkinElmer Announces Financial Results for the Second Quarter of 2017 46

May 04, 2017: PerkinElmer Announces Financial Results for the First Quarter of 2017 47

Feb 02, 2017: PerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2016 48

Corporate Communications 50

Apr 10, 2018: PerkinElmer Names James Mock as Chief Financial Officer 50

Oct 30, 2017: PerkinElmer Elects Pascale Witz to its Board of Directors 51

Sep 15, 2017: PerkinElmer Announces Future Retirement of Andy Wilson, Chief Financial Officer 52

Product News 53

Oct 31, 2017: Phase II Clinical Trial Data Establishes Effectiveness of using a Child's Own Cord Blood to Treat Cerebral Palsy 53

Mar 23, 2017: PerkinElmer to Display Portfolio of Cancer Research Technologies and Workflow Solutions at 2017 AACR Annual Meeting 54

Jan 23, 2017: PerkinElmer's NexION 2000 ICP-MS Provides Industry-Leading Versatility for Trace Elemental Analyses 56

Other Significant Developments 57

Apr 05, 2018: Parent Project Muscular Dystrophy Selects PerkinElmer to Support Decode Duchenne Program 57

Sep 07, 2017: PerkinElmer Extends Clinical Whole Genome Sequencing Services 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

PerkinElmer Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

PerkinElmer Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PerkinElmer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PerkinElmer Inc, Deals By Therapy Area, 2012 to YTD 2018 9

PerkinElmer Inc, Medical Devices Deals, 2012 to YTD 2018 10

PerkinElmer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Enzyvant Enters into Collaboration Agreement PerkinElmer 13

Nightingale Health Enters into Agreement with PerkinElmer 14

PerkinElmer Forms Joint Venture with Genome Institute of Singapore 15

Albany Molecular Research Enters into Agreement with PerkinElmer 16

Reproductive Health Science Enters into Distribution Agreement with Delfran Pharma 17

Transgenomic Enters Into Co-Marketing Agreement With PerkinElmer For Oncology Diagnostic Test Portfolio 18

ViaCord Enters Into Agreement With Center for International Blood and Marrow Transplant Research For Stem Cell Therapy Research 19

PerkinElmer Enters Into Agreement With National Center for Drug Screening 20

Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 21

Integromics Enters Into Co-Development Agreement With Galician Foundation Of Genomic Medicine 22

Bioo Scientific Enters into Licensing Agreement with Icahn School of Medicine 23

Trinean Enters Into Licensing Agreement With Perkinelmer For Microfluidics Technology 24

PerkinElmer Raises USD370.1 Million in Public Offering of 0.6% Notes Due 2021 25

PerkinElmer Raises EUR553 Million in Public Offering of 1.875% Notes Due 2026 26

PerkinElmer to Acquire RHS for up to USD19.7 Million 27

PerkinElmer Acquires Bioo Scientific for USD63.5 Million 28

PerkinElmer Acquires Ceiba Solutions 29

AO Energy Completes Acquisition of Reproductive Health Science 30

PerkinElmer Acquires Shanghai Haoyuan Biotech From Medigen Biotech 31

PerkinElmer Inc, Key Competitors 32

PerkinElmer Inc, Key Employees 33

PerkinElmer Inc, Other Locations 34

PerkinElmer Inc, Subsidiaries 35

PerkinElmer Inc, Joint Venture 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

PerkinElmer Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.